Compagnie Lombard Odier SCmA’s Altamira Therapeutics Ltd CYTO Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio CYTO Stock Details CYTO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-10	Closed	-$28K	–	615
2018 Q3	$28K	Buy	+10	New	+$26.3K	﹤0.01%	475

Other funds holding CYTO

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

CGA

Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Compagnie Lombard Odier SCmA's CYTO Position: Q4 2018 in Review

Compagnie Lombard Odier SCmA sold out of Altamira Therapeutics Ltd (CYTO) in Q4 2018, closing a stake of 10 shares — an estimated $28K sold.

Compagnie Lombard Odier SCmA first reported a position in CYTO in Q3 2018 and held it in 1 quarter. The position peaked at $28K in Q3 2018. 8 funds tracked by Wall St. Rank hold CYTO as of Q4 2018.

Compagnie Lombard Odier SCmA reported no remaining Altamira Therapeutics Ltd position as of Q4 2018 after selling out during the quarter.
Compagnie Lombard Odier SCmA sold 10 Altamira Therapeutics Ltd shares in Q4 2018, an estimated $28K.
Compagnie Lombard Odier SCmA first reported a position in Altamira Therapeutics Ltd in Q3 2018 and held it in 1 quarter.
Compagnie Lombard Odier SCmA's Altamira Therapeutics Ltd position peaked at $28K in Q3 2018.
8 funds tracked by Wall St. Rank held Altamira Therapeutics Ltd as of Q4 2018.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q4 2018, filed 13 Feb 2019.